← All Spyre Therapeutics, INC filings

Spyre Therapeutics, INC S-1 registration statements

Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.

NASDAQ
SYRE
Spyre Therapeutics, INC
S-1: Spyre Therapeutics Files for Resale of 33.4 Million Shares Following PIPE Investments
Spyre Therapeutics aims to register the resale of up to 33.4 million shares of its common stock by selling stockholders after recent private placements.
NASDAQ
SYRE
Spyre Therapeutics, INC
S-1/A: Spyre Therapeutics Files Amendment for Resale of 12 Million Shares
Spyre Therapeutics is filing an amendment to its registration statement for the resale of up to 12 million shares of its common stock by selling stockholders.
NASDAQ
SYRE
Spyre Therapeutics, INC
S-1/A: Spyre Therapeutics Registers 12 Million Shares for Resale by Selling Stockholders Following $180 Million PIPE Deal
Spyre Therapeutics has filed a registration statement for the resale of 12 million shares of common stock by selling stockholders, following a recent private placement that raised $180 million.
NASDAQ
SYRE
Spyre Therapeutics, INC
S-1/A: Spyre Therapeutics Files Amendment to S-1 Registration for Stock Resale
Spyre Therapeutics files an amendment to its S-1 registration statement, covering the resale of up to 12 million shares of common stock by selling stockholders.
NASDAQ
SYRE
Spyre Therapeutics, INC
S-1/A: Spyre Therapeutics Bolsters Pipeline with Asset Acquisition, Announces Executive Changes
Spyre Therapeutics completes an asset acquisition to enhance its IBD pipeline and announces key executive appointments and board changes.